Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01473602 · ClinicalTrials.gov registry record · Phase 3
Second Study of the Effect of Teriparatide on Hip Fracture Healing
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT01473602: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01473602 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 39 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01473602, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age with a recent hip (femoral neck) fracture caused by low-trauma (for example, fall from standing height or less).
Primary Outcome
Revision surgery (re-operation) was defined as any additional surgical intervention performed or recommended at the site of the index procedure, except those that were planned at the time of the index procedure.
Interventions
- DRUG Placebo
- DRUG Teriparatide
- DIETARY_SUPPLEMENT Vitamin D supplementation
- DIETARY_SUPPLEMENT Calcium supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
What the finished NCT01473602 record still lists
NCT01473602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01473602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01473602 about?
NCT01473602 is a clinical study titled "Second Study of the Effect of Teriparatide on Hip Fracture Healing". The purpose of this study is to see whether teriparatide, given for 6 months versus placebo, will improve the healing of hip (femoral neck) fractures that are repaired during surgery using certain types of orthopedic screws. The study will enroll men and postmenopausal women at least 50 years of age...
What is the current status of trial NCT01473602?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 2012-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01473602?
The interventions under investigation include: Placebo (DRUG), Teriparatide (DRUG), Vitamin D supplementation (DIETARY_SUPPLEMENT), Calcium supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01473602?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01473602's enrollment target sits among peer trials
39 1898th of 2000 higher than 101 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia